Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

NovoCure (NVCR) Stock Price & Analysis

1,590 Followers

NVCR Stock Chart & Stats

$13.28-$0.27(-1.99%)
At close: 4:00 PM EST
$14$16$18Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$13.06 - $13.59
52-Week Range
$9.82 - $21.45
Previous Close
$13.55
Volume
N/A
Average Volume (3M)
1.77M
Market Cap
$1.58B
Enterprise Value
$1.62B
Total Cash (Recent Filing)
$463.48M
Total Debt (Recent Filing)
$231.55M
Price to Earnings (P/E)
―
Beta
1.31
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
-0.22
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Patient And Revenue Growth

Growth in active patients and revenue indicates expanding adoption of TTFields rather than reliance solely on pricing or one-time transactions. A larger treated population can support recurring therapy-related revenue, improve commercial scale, and strengthen the company’s platform across existing and new indications.

Improving Margins And EBITDA

Gross margin in the high 70s provides a strong product-level economic base, while positive quarterly adjusted EBITDA shows progress toward operating leverage. If sustained as revenue expands, these economics could help fund commercialization and reduce dependence on external financing over time.

Japanese Market Expansion

Japanese approval expands OptunePax into a major international market and adds a new reimbursable treatment opportunity beyond existing geographies. The approval is supported by statistically significant overall-survival improvement, creating a durable basis for commercial expansion if reimbursement and adoption develop as expected.

Bears Say

Unprofitable And Cash-Consuming

Despite revenue growth and improving losses, NovoCure remains unprofitable and is not yet consistently self-funding. Negative free cash flow limits internal funding for clinical development and launches, while continued execution is required before profitability can provide a durable source of financial flexibility.

OptunePax U.S. Launch Slowdown

A slower U.S. launch for OptunePax could delay the product’s contribution to growth and reduce the near-term return on commercialization investment. The issue is more material because expansion depends on building prescribing activity and practice access in a new indication.

Reimbursement Dependence

NovoCure’s recurring therapy revenue depends on third-party reimbursement and successful authorization of eligible patients, not just clinical demand. Changes in payer coverage, reimbursement rates, or claims processing can constrain patient access, lengthen collections, and make expansion into new indications less predictable.

NovoCure News

NVCR FAQ

What was NovoCure’s price range in the past 12 months?
NovoCure lowest stock price was $9.82 and its highest was $21.45 in the past 12 months.
What is NovoCure’s market cap?
NovoCure’s market cap is $1.58B.
When is NovoCure’s upcoming earnings report date?
NovoCure’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 110 days.
How were NovoCure’s earnings last quarter?
NovoCure released its earnings results on Oct 29, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.235 by $0.145.
Is NovoCure overvalued?
According to Wall Street analysts NovoCure’s price is currently Undervalued.
Does NovoCure pay dividends?
NovoCure does not currently pay dividends.
What is NovoCure’s EPS estimate?
NovoCure’s EPS estimate is -0.22.
How many shares outstanding does NovoCure have?
NovoCure has 116,915,960 shares outstanding.
What happened to NovoCure’s price movement after its last earnings report?
NovoCure reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.235. Following the earnings report the stock price went down -7.481%.
Which hedge fund is a major shareholder of NovoCure?
Hedge funds hold NovoCure shares: the largest hedge-fund position in NovoCure is 71,886,001 shares, and hedge funds increased their holdings by 219.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology